KALV250516C10000
- 0.00
- 0.000.00%
KalVista Pharmaceuticals Newsroom
JMP Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $19
BofA Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $22
Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $28
JMP Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $19
JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $30
KalVista Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Humana (HUM) and PROCEPT BioRobotics (PRCT)
A Quick Look at Today's Ratings for KalVista Pharmaceuticals(KALV.US), With a Forecast Between $28 to $39
KalVista Pharmaceuticals' Strategic Readiness and Market Potential Drive Buy Rating for Sebetralstat
Analysts' Opinions Are Mixed on These Healthcare Stocks: Theratechnologies (THTX), KalVista Pharmaceuticals (KALV) and Mereo Biopharma Group Plc (MREO)
KalVista Pharmaceuticals Price Target Maintained With a $30.00/Share by Jones Trading
KalVista Pharmaceuticals Is Maintained at Buy by Jones Trading
KalVista Pharma Analyst Ratings
BofA Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $22
JMP Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $19
BofA Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $22
Buy Rating for KalVista Pharmaceuticals: Strong Regulatory Progress and Market Potential for Sebetralstat
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
KalVista Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Cuts Target Price to $30